المؤلفون: Agoston Gyula Szabo (11559096), Tobias Wirenfeldt Klausen (6893171), Mette Bøegh Levring (11559099), Birgitte Preiss (4669333), Carsten Helleberg (4669348), Marie Fredslund Breinholt (9615164), Emil Hermansen (11559102), Lise Mette Rahbek Gjerdrum (10200536), Søren Thorgaard Bønløkke (11559105), Katrine Nielsen (11559108), Eigil Kjeldsen (587943), Katrine Fladeland Iversen (11559111), Elena Manuela Teodorescu (4669342), Marveh Dokhi (11559114), Eva Kurt (11559117), Casper Strandholdt (11559120), Mette Klarskov Andersen (11559123), Annette Juul Vangsted (11559126)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Neuroscience, Pharmacology, Biotechnology, Immunology, Developmental Biology, Cancer, Infectious Diseases, overall response rate, multivariate analysis indicated, +information%22">xlink "> information, patients received throughout, randomized clinical trials, +daratumumab%22">xlink "> daratumumab, daratumumab , 635 patients treated, standard risk patients, %22">xlink ">, clinical trials, risk ca, patients treated, patients cannot, danish patients, world outcomes, similar outcomes, proteasome inhibitors, outcomes achieved, multiple myeloma

Relation: https://figshare.com/articles/journal_contribution/S1_File_-/16804686

الاتاحة: https://doi.org/10.1371/journal.pone.0258487.s001

المؤلفون: Agoston Gyula Szabo (11559096), Tobias Wirenfeldt Klausen (6893171), Mette Bøegh Levring (11559099), Birgitte Preiss (4669333), Carsten Helleberg (4669348), Marie Fredslund Breinholt (9615164), Emil Hermansen (11559102), Lise Mette Rahbek Gjerdrum (10200536), Søren Thorgaard Bønløkke (11559105), Katrine Nielsen (11559108), Eigil Kjeldsen (587943), Katrine Fladeland Iversen (11559111), Elena Manuela Teodorescu (4669342), Marveh Dokhi (11559114), Eva Kurt (11559117), Casper Strandholdt (11559120), Mette Klarskov Andersen (11559123), Annette Juul Vangsted (11559126)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Neuroscience, Pharmacology, Biotechnology, Immunology, Developmental Biology, Cancer, Infectious Diseases, overall response rate, multivariate analysis indicated, +information%22">xlink "> information, patients received throughout, randomized clinical trials, +daratumumab%22">xlink "> daratumumab, daratumumab , 635 patients treated, standard risk patients, %22">xlink ">, clinical trials, risk ca, patients treated, patients cannot, danish patients, world outcomes, similar outcomes, proteasome inhibitors, outcomes achieved, multiple myeloma

Relation: https://figshare.com/articles/figure/Time_to_next_treatment_and_overall_survival_of_the_first_daratumumab_therapy_/16804689

الاتاحة: https://doi.org/10.1371/journal.pone.0258487.g001

المؤلفون: Agoston Gyula Szabo (11559096), Tobias Wirenfeldt Klausen (6893171), Mette Bøegh Levring (11559099), Birgitte Preiss (4669333), Carsten Helleberg (4669348), Marie Fredslund Breinholt (9615164), Emil Hermansen (11559102), Lise Mette Rahbek Gjerdrum (10200536), Søren Thorgaard Bønløkke (11559105), Katrine Nielsen (11559108), Eigil Kjeldsen (587943), Katrine Fladeland Iversen (11559111), Elena Manuela Teodorescu (4669342), Marveh Dokhi (11559114), Eva Kurt (11559117), Casper Strandholdt (11559120), Mette Klarskov Andersen (11559123), Annette Juul Vangsted (11559126)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Neuroscience, Pharmacology, Biotechnology, Immunology, Developmental Biology, Cancer, Infectious Diseases, overall response rate, multivariate analysis indicated, +information%22">xlink "> information, patients received throughout, randomized clinical trials, +daratumumab%22">xlink "> daratumumab, daratumumab , 635 patients treated, standard risk patients, %22">xlink ">, clinical trials, risk ca, patients treated, patients cannot, danish patients, world outcomes, similar outcomes, proteasome inhibitors, outcomes achieved, multiple myeloma

Relation: https://figshare.com/articles/dataset/Summary_of_characteristics_and_outcome_of_635_patients_treated_with_daratumumab_/16804698

الاتاحة: https://doi.org/10.1371/journal.pone.0258487.t001

المؤلفون: Agoston Gyula Szabo (11559096), Tobias Wirenfeldt Klausen (6893171), Mette Bøegh Levring (11559099), Birgitte Preiss (4669333), Carsten Helleberg (4669348), Marie Fredslund Breinholt (9615164), Emil Hermansen (11559102), Lise Mette Rahbek Gjerdrum (10200536), Søren Thorgaard Bønløkke (11559105), Katrine Nielsen (11559108), Eigil Kjeldsen (587943), Katrine Fladeland Iversen (11559111), Elena Manuela Teodorescu (4669342), Marveh Dokhi (11559114), Eva Kurt (11559117), Casper Strandholdt (11559120), Mette Klarskov Andersen (11559123), Annette Juul Vangsted (11559126)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Neuroscience, Pharmacology, Biotechnology, Immunology, Developmental Biology, Cancer, Infectious Diseases, overall response rate, multivariate analysis indicated, +information%22">xlink "> information, patients received throughout, randomized clinical trials, +daratumumab%22">xlink "> daratumumab, daratumumab , 635 patients treated, standard risk patients, %22">xlink ">, clinical trials, risk ca, patients treated, patients cannot, danish patients, world outcomes, similar outcomes, proteasome inhibitors, outcomes achieved, multiple myeloma

Relation: https://figshare.com/articles/figure/Time_to_next_treatment_of_the_first_daratumumab_therapy_depending_on_cytogenetic_abnormalities_/16804695

الاتاحة: https://doi.org/10.1371/journal.pone.0258487.g003